Evidence map›Paper›PMID 27062485›Full record

ArticleJournal of nephrology2017

A comparison of three induction therapies on patients with delayed graft function after kidney transplantation.

Afia Umber, Mary Killackey, Anil Paramesh, Yongjun Liu, Huaizhen Qin, Muhammad Atiq, Belinda Lee, Arnold Brent Alper, Eric Simon, Joseph Buell and 1 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Afia UmberSection of Nephrology and Hypertension, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, USA.
Mary KillackeyDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA, 70112, USA.
Anil ParameshDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA, 70112, USA.
Yongjun LiuDepartment of Biostatistics, Tulane University School of Public Health and Tropic Medicine, New Orleans, LA, USA.
Huaizhen QinDepartment of Biostatistics, Tulane University School of Public Health and Tropic Medicine, New Orleans, LA, USA.
Muhammad AtiqSection of Nephrology and Hypertension, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, USA.
Belinda LeeSection of Nephrology and Hypertension, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, USA.
Arnold Brent AlperSection of Nephrology and Hypertension, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, USA.
Eric SimonSection of Nephrology and Hypertension, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, USA.
Joseph BuellDepartment of Surgery, Tulane University School of Medicine, New Orleans, LA, 70112, USA.
Rubin ZhangSection of Nephrology and Hypertension, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, USA. rzhang@tulane.edu.
Tulane University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We compare the outcomes of induction therapies with either methylprednisolone (group 1, n = 58), basiliximab (group 2, n = 56) or alemtuzumab (group 3, n = 98) in primary deceased donor kidney transplants with delayed graft function (DGF). Protocol biopsies were performed. Maintenance was tacrolimus and mycophenolate with steroid (group 1 and 2) or without steroid (group 3). One-year biopsy-confirmed acute rejection (AR) rates were 27.6, 19.6 and 10.2 % in group 1, 2 and 3 (p = 0.007). AR was significantly lower in group 3 (p = 0.002) and group 2 (p = 0.03) than in group 1. One-year graft survival rates were 90, 96 and 100 % in group 1, 2 and 3 (log rank p = 0.006). Group 1 had inferior graft survival than group 2 (p = 0.03) and group 3 (p = 0.002). The patient survival rates were not different (96.6, 98.2 and 100 %, log rank p = 0.81). Multivariable analysis using methylprednisolone induction as control indicated that alemtuzumab (OR 0.31, 95 % CI 0.11-0.82; p = 0.03) and basiliximab (OR 0.60, 95 % CI 0.23-0.98; p = 0.018) were associated with lower risk of AR. Therefore, alemtuzumab or basiliximab induction decreases AR and improves graft survival than methylprednisolone alone in patients with DGF. Alemtuzumab induction might also allow patients with DGF to be maintained with contemporary steroid-withdrawal protocol.

Indexed as

AdultAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBasiliximabChi-Square DistributionDelayed Graft FunctionFemaleGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsInduction ChemotherapyKaplan-Meier EstimateKidneyKidney TransplantationAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBasiliximabImmunosuppressive AgentsMethylprednisoloneRecombinant Fusion ProteinsAcute rejectionAlemtuzumabBasiliximabDelayed graft functionGraft survivalInduction therapyKidney transplantSteroid withdrawal

Identifiers

PMID27062485
OpenAlexW2333017548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.